Encyclopedia entry
MOTS-c
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-16
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · MOTS-c
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, first characterised by the Cohen lab at USC in 2015. Roughly 200 preclinical papers describe roles in metabolic regulation, insulin sensitivity and late-life healthspan in mouse models. No human RCTs of exogenous MOTS-c administration have been published.
Top UK MOTS-c retailers
Mechanism of action
How MOTS-c works
MOTS-c is encoded within the 12S ribosomal RNA region of mitochondrial DNA and translates a 16-amino-acid peptide that translocates to the nucleus under metabolic stress. The proposed action is regulation of AMP-activated protein kinase (AMPK) signalling, with downstream effects on insulin sensitivity, glucose uptake and mitochondrial biogenesis. The human receptor target is not formally established.
Source: Lee C et al. Cell Metabolism, 2015 (original characterisation)
Key publications
MOTS-c has roughly 200 papers on PubMed across the decade since the Cohen lab characterised it in 2015. The Reynolds 2021 Nature Communications paper on late-life mouse administration is the most-cited preclinical reference for the longevity hypothesis. No human RCTs of exogenous MOTS-c have been published in any indication.
- · Lee C et al. Cell Metabolism 2015. Original characterisation of MOTS-c as a mitochondrial peptide regulating insulin sensitivity.
- · Reynolds JC et al. Nature Communications 2021. Late-life MOTS-c administration in mice extended healthspan.
- · Several smaller mouse studies on exercise capacity and metabolic flexibility.
What is not known
Despite a decade of preclinical interest there are zero human RCTs of exogenous MOTS-c. Effective dose, route, half-life and pharmacokinetics in humans remain uncharacterised. The translation from mouse healthspan to human longevity is theoretical.
- · No published human RCTs of exogenous MOTS-c.
- · No UK or US marketing authorisation.
- · Effective dose, route and pharmacokinetics in humans are not established.
- · Long-term safety in humans is not established.
UK regulatory framing
Sold by UK research-peptide retailers under "research use only, not for human or animal consumption" framing. Same regulatory tier as BPC-157. We do not publish dosing or human-use protocols. See the UK retailer comparison.
Researchers comparing metabolic-target compounds often encounter MOTS-c alongside 5-Amino-1MQ (a small-molecule NNMT inhibitor, not a peptide) and tesamorelin. Each acts by an entirely different mechanism.
Risks and unknowns
What the literature does not yet show about MOTS-c
Known concerns
- No published human RCT data on safety profile or long-term tolerability.
- Mouse-to-human translation for longevity claims is unvalidated.
- Purity of UK research-peptide supply varies; CoA gating differs across retailers.
- Cold-chain handling between manufacture and delivery is not standardised in the research-peptide market.
Open questions in the literature
- Optimal route of administration in humans is not established.
- Pharmacokinetics in humans (half-life, clearance) are not characterised.
- Long-term effects on insulin signalling and mitochondrial biogenesis in humans are unknown.
- Interaction with endogenous mitochondrially-encoded peptides under chronic administration is unstudied.
Regulatory note
Not controlled under UK law. No UK marketing authorisation as a medicine. Sold legally as a research chemical when marketed without therapeutic claims. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Frequently asked questions
Is MOTS-c legal in the UK?
What does the human evidence show for MOTS-c?
What is the regulatory status of MOTS-c?
What forms is MOTS-c available in?
Where can I learn more about MOTS-c?
Where to buy MOTS-c in the UK
Side-by-side price comparison across UK research peptide retailers. Trust Index ranking. Research use only.
Compare UK retailersClinical evidence record
Read the clinical evidence record for MOTS-c
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy MOTS-c in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.